RARA and acute promyelocytic leukemia: The greatest success was the introduction of all-trans retinoic acid (ATRA) to treat a subtype of AML, acute promyelocytic leukemia (APL), where the retinoic acid receptor α gene (RARA) is fused to the promyelocytic leukemia gene (PML) due to a chromosomal translocation [6].